Novo Nordisk (NYSE: NVO) stock is in a funk. Monday's decline probably owes to rival GLP-1 company Hims & Hers Health running ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

the fastest-growing segment for Novo Nordisk. This past 2024, despite a 33% drop in Saxenda sales, this area grew by 56%, driven by the incredible 85% annual growth of Wegovy. Even with increasing ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Novo Nordisk, the Danish pharmaceutical giant that makes Ozempic and Wegovy, used a submission to the government’s budget process to push for the inclusion of so-called GLP-1 drugs on the PBS ...

COPENHAGEN--Novo Nordisk will launch its hugely popular anti-obesity drug Wegovy in Japan on Feb. 22 next year, its first launch in Asia, the company said on Thursday, even as it struggles to keep ...

Novo Nordisk's obesity therapy Wegovy put in another strong sales performance in the final quarter of last year, helping to drive group revenue growth of 30% – but don't expect that breakneck ...

Novo Nordisk sells the drug under the brand names Wegovy to treat obesity and heart disease and Ozempic to treat Type 2 diabetes. Compounding pharmacies are regulated by state boards of pharmacy ...

Ozempic and Wegovy come in special injector pens that make it easy to get the dosing right. But the company that makes those drugs, Novo Nordisk, has the exclusive right to make those injector pens.

Novo Nordisk is also developing an oral drug for obesity, amycretin, which also performed better than Wegovy in a phase 3 obesity trial and is in mid-stage development. New approval for Zepbound ...

The luster is starting to wear off GLP-1 weight-loss drugs including Wegovy and Ozempic as more clinicians warn patients ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...